Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.41 |
| ▸ | NSD2 | O96028 | 3/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 5/20 | 0.37 |
| ▸ | CDC25B | P30305 | 3/20 | 0.37 |
| ▸ | PTPRC | P08575 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021274 | 0.73 | S100A4 (0.41) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL15405526 | 0.72 | S100A4 (0.40) | TDP2NSD2PAX8TDP1ABL1 | |
| Hydrochloric Acid SCHEMBL31127657 | 0.72 | S100A4 (0.40) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL30503628 | 0.72 | S100A4 (0.40) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL19423556 | 0.72 | S100A4 (0.40) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL6949593 | 0.71 | — | — | |
| SCHEMBL3590145 | 0.70 | HSP90AA1 (0.39) | TDP2NSD2PAX8TDP1ABL1 | |
| SCHEMBL24981816 | 0.69 | TDP2 (0.45) | TDP2NSD2PAX8TDP1ABL1 | |
| Hydrochloric Acid SCHEMBL31586638 | 0.69 | PDE3B (0.33) | TDP1KDM4EHIF1A | |
| SCHEMBL30083032 | 0.69 | TDP2 (0.45) | TDP2NSD2PAX8TDP1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268638-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009121812-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-10-08 | — | — | WO | claimed |
| EP-2268638-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | TDP2 2361/4885NSD2 1738/4885PAX8 4688/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | TDP2 2361/4885NSD2 1738/4885PAX8 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.